Blog #2.5

Give a short and critical explanation of the rationale of using fluvoxamine (a selective serotonin reuptake inhibitor (SSRI) in the treatment of Covid patients:

Fluvoxamine has a high affinity for the S1R (ER-resident protein sigma-1-receptor). This sppecific receptor is responsible for the restriction of endonuclease activity of the Endoplasmic reticulum stress sensor, IRE1. It restricts cytokine expression. Fluvoxamine does not inhibit inflammatory signaling pathways. The cytokine expression acts as an inflammation-causing symptom in COVID-19. With this, Fluvoxamine decreases the inflammatory response in human blood leukocytes. therefore, fluvoxamine is being researched as a possible treatment option for the Covid-19 virus.